ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Advisors Ok New RFP For Natural Product Large-Scale Production

March 6, 1992

ICCCR Participants Honor Cullen, Blast Tobacco Industry

March 15, 1991

NCI Has Congressional Mandate Fr Planning Clinical Trials of Unconventional Therapies, Chabner Says

June 5, 1992

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

May 2, 2008

In Brief: Phillip Sharp Selected Next MIT President; Montgomery Retires From SRI Administration

February 23, 1990

NCI Proposes Consolidation of Nine Cooperative Groups to Four

December 17, 2010